Local market adaptations of economic models in anaesthesia (for neuromuscular block)
Payer value deck in neuromuscular block
Development of a conceptual framework and SAP for a treatment for neuromuscular block
Treatment effect analyses based on a Quality of Recovery questionnaire (QoR-40) and Reversal Agent Satisfaction Questionnaire (RASQ) in neuromuscular block
Core value dossier update in chronic/neuropathic pain
Update of core value dossier and value story in chronic neurological pain
Manuscript based on burden of illness study in neuropathic pain for submission to peer-reviewed journal
Rapid payer research to support investment decisions in neuropathic pain
Payer interviews in neuropathic pain
Mapping out and costing of care pathways for neuropathic pain
Use of focus groups for the assessment of PROs in neuropathic pain
Assessment of PROs in neuropathic pain
Consultation on an observational study in neuropathic pain: review of protocol and SAP to ensure that an appropriate PRO strategy can be developed for phase III studies
PRO analyses in neuropathic pain
Patient focus groups to validate a conceptual model in neuropathic pain
Translation of the Neuropathic Pain Symptom Inventory (NPSI)
Development of a screening tool for opioid dependence
Endpoint review and qualitative research in opioid addiction
Interviews and Rasch analysis in opioid addiction
Psychometric validation of the clinical opiate withdrawal scale (COWS), subjective opiate withdrawal scale (SOWS) and craving visual analog scale (VAS) in opioid withdrawal symptoms
Preparation of three core European value dossiers (for use by affiliates and targeted to regional/local decision makers in key markets) and three value stories in haematology
Manuscript on a budget impact model for a biosimilar in haematology
Revisions to the Lymphoedema Quality of Life Questionnaire (LYMQOL)
Payer and pricing research and landscape analysis of hygiene product reimbursement and funding flow in UK hospitals for hospital acquired infections
HEOR team capabilities audit and training plan in infectious diseases
Literature review and development of a suite of dossiers in anti-infectives (anti-bacterial resistance)
Development of an e-v@luate EVIDENCE platform for a vaccines portfolio
Literature review of antibiotic resistance
Cost effectiveness analysis model for Portugal on a treatment for bacterial diabetic foot infections
Suite of dossiers for an anti-infective in gram-negative infections
Cost-effectiveness model for cytomegalovirus (CMV) prophylaxis in kidney transplant recipients
Pharmacoeconomic and PRO design and analysis for an immunoglobulin product
Analysis in an EU study in primary immunodeficiency
Pricing reimbursement overview for the UK for a novel anti-viral treatment
Cost effectiveness model on a treatment for bacterial infections
Cost-effectiveness analysis of a treatment of intra-abdominal infections in the USA
Global value dossier, slide deck and FAQs on antibiotic resistance in gram-negative infections
Update to an anti-infectives dossier in gram negative bacterial infections
Estimating the return on investment from investing in adult immunisation in Europe
Strategic access objectives in infectious diseases
Development of a manuscript and consultation on economic evaluations alongside a clinical trial in intra-abdominal infections
Structured literature review and value strategic insight to understand the prevalence and burden of vaccine-preventable diseases (haemophilus influenzae, hepatitis A & B, HPV-associated cancers, influenza, measles, mumps, rubella, meningococcal disease, pneumonia, tetanus, diphtheria, whooping cough, chicken pox, and shingles) amongst sub-populations identified in the ACIP recommendations
Protocol, CRF and distress diary development in infectious diseases
COA consultancy support and validation of a nasal congestion scale
Economic analysis and trial design in hip replacement
Payer value slide deck in muscle relaxation management
Manuscript on a budget impact model for a biosimilar in rheumatology
General consultancy on economic and quality of life endpoints in planned trials in several musculoskeletal disease indications
Measurement strategy to demonstrate efficacy of medical devices in patients with pigmented villonodular synovitis (PVNS) or tenosynovial giant cell tumour (dTGCT)
Review adherence questionnaire in a musculoskeletal disease
Scenario model and value messages for oncology in Australia, France, Austria, Switzerland, Belgium, Germany, Italy, Slovenia and the Netherlands
Scenario model and policy messages in oncology (Health Impact Projection) for Korea, Norway and Germany
Development of a slide deck on the Health Impact Projection in oncology for presentation at a conference
Development of an evidence evaluation framework in cancer
Creative values demonstration in oncology
Budget impact model and clinical data update for the Health Impact Projection in oncology
Training on a UK budget impact model for a chemotherapy drug
External communications for a multi-indication value-based pricing model in oncology
Value based pricing model manuscript in oncology
Adaptation of a value-based pricing multi-indication global model in oncology to Belgium and the US
Cost utility model and pilot version of the Safety Profile Model for oncology
Economic model for an erythropoietin treatment in cancer
Extension and creation of economic evidence on an erythropoietin treatment in cancer
Burden of disease deck on biomarkers in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) advanced (stage IV) cancerous tumours
Payer value deck on biomarkers in MSI-H or dMMR advanced (stage IV) cancerous tumours
Response to payer questions on biomarkers in MSI-H or dMMR advanced (stage IV) cancerous tumours
Response to payer questions update on biomarker response in various cancer indications
Support for the commercialisation of treatment for an immune-response modifier in oncology
Competitor intelligence tracking in oncology
Implementation guide in all indications of oncology
Frequently asked questions deck in oncology biomarkers and companion diagnostics
EU market access training in oncology
Steering committee meeting in oncology
Face-to-face meeting with external experts for review and validation of scenario policy model in oncology
Country-level advisory board for a health impact model in oncology
Country specific advisory board for the Health Impact Projection model for the Netherlands
One-day workshop on Health Impact Projection in oncology
Slovenia-focused advisory board on the Health Impact Projection tool in oncology
Literature and reimbursement review of IV versus SC oncology therapies, and development of a conference poster
Systematic literature review on oncology drugs that have made the switch from IV to SC formulation
Literature review and consultancy on oncology
Budget impact model on an oncology biosimilar
Budget impact model for a biosimilar in multiple oncology indications
Health Economics and Outcomes Research (HEOR) training academy in oncology
Development of an abstract to communicate a systematic literature review in oncology
Development of a poster on IV and SC therapies in immuno-oncology
Health Impact Projection expert meeting on oncology
Development of a poster on a systematic review of real-world outcomes of IV and SC therapies in oncology
Value-based pricing model in oncology for Belgium
Reimbursement scenario analysis for a Korean Health Impact Projection model in oncology
Multi-indication budget impact and resource utilisation model in oncology
Access landscape analysis for remote care coordination in oral oncotherapy
Multi-indication cost-effectiveness model in oncology for Korea
HE support for launch of a new immunotherapy dose in oncology
Manuscript on a multi-indication cost-effectiveness model in oncology for Korea
Value evidence compendium in pan-tumour oncology
Development of a Health Impact Projection model in oncology for Korea, Turkey, Australia and other countries in Europe and Globally
Adaptations of a Health Impact Projection model to Japan, Turkey, Portugal, Australia, New Zealand and Hong Kong
PRO consulting for regulatory affairs and investigator training slides in malignant ascites
PRO endpoint consulting in oncology
Clinical investigator PROs for chemotherapy trials
Comprehensive PRO strategy in oncology
Support in the development of a PRO strategy for four compounds in 6-8 oncology indications
PRO booklet review and edits adaptation on cancer
Selection and implementation of PROs such as health-related quality of life and symptoms assessment in the clinical development of new compounds in the field of oncology
Consultancy in administration of PROs in a clinical oncology trial
Statistical review of PRO aspects of an oncology protocol
EMEA training on PROs in haematology and oncology
Identification of PRO measures suitable for implementation in phase III oncology and immunotherapy trials
Strategic consulting on PRO endpoints for FDA approvable claims
Development of a PRO best practices document – interactions with international regulatory and HTA agencies in oncology
PRO oncology workshop
Development of a PRO dossier for the Cancer Therapy Satisfaction Questionnaire (CTSQ) for the FDA
Carcinoid protocol review and outcomes strategy in oncology
Develop a reimbursement submission checklist in oncology
Consulting and participation in an EU/USA payer advisory board meeting on oncology
HEOR strategic consulting in oncology
Consulting and exploratory analysis of clinical trials of an intravenous drug treatment for cancer
Training session on health economics and outcomes research (HEOR) in oncology
Advisory board meeting on oncology
Strategic consultancy on recommendations of efficacy analyses in oncology using PRO data
Symposium oral presentation on clinical trial analyses to support health-related quality of life in oncology
Support MRI and qualitative analyses to document conceptual equivalence of an additional linguistic version of the Ascites Impact Measure (AIM) questionnaire
Development and validation of a measure of symptomatic malignant ascites leading to paracentesis for relief of abdominal discomfort
Assessment of the disease & TX-related symptoms and concepts for 7 oncology indications, and comparison to available measurement tools
Development and validation of a generic chemotherapy instrument
Psychometric validation of the Cancer Chemotherapy Satisfaction Questionnaire
Oncology post trial questionnaire, strategic review and content validation
Strategic review and content validation of a measure to evaluate the experience of participating in a clinical trial in oncology
Manuscript on the validation of the Cancer Therapy Satisfaction Questionnaire (CTSQ)
Literature review on autonomy for an intravenous drug treatment for cancer
Preferences and experiences of cancer patients and their families
Cognitive debriefing interviews for the development of a generic chemotherapy instrument
Team presentation on how to develop a PRO measure and interact with the FDA in oncology
Comparison of a generic EQ-5D-3L utility measure to new cancer-specific utility measure (QLU-C10D) and the EQ-5D-3L/5L cross-walks
Decision-making survey on granulocyte colony stimulating factor (G-CSF) in oncology
Review and confirmation of content validity of an existing cancer quality of life tool
Validation and implementation of a cancer tool to asses doctor and patient communication
Cognitive debriefing interviews to confirm the face and content validity of the modified cancer care plan communication tools
Development of an evidence evaluation framework in cancer
Slides to outline the intravitreal injection process in the UK
Healthcare resource costing study for dry eye disease in the UK
Two mini value dossiers in glaucoma
Value messages and objection handlers for anti-vascular endothelial growth factor therapy (anti-VEGF) treatment in diabetic retinopathy and retinopathy of prematurity
Utility study feasibility assessment in retinitis pigmentosis
Health utilities in thyroid disease induced proptosis and diplopia
Exploratory analysis of phase II clinical trial data for acute optic neuritis
Manuscript on health-related quality of life trial results of a new lens
Analysis of focus group results in post-Lasik corneal sensitivity
Development and validation of a pterygium instrument
Development of a briefing document on a visual function questionnaire
PRO review of the subjective eyelid swelling scale for patients with eyelid swelling upon awakening in the morning
Analysis and reporting on completed interviews about eyelid swelling
Literature review of retinopathy of prematurity
Review of PRO measures in diabetic macular edema
Development of a PRO measure to assess impacts of full eye rejuvenation
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsRead MoreACCEPTREJECT
Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
We’d like to set analytic software i.e. Google Analytics/Click Dimensions to help us improve our website by collecting and reporting information on how you use it. The cookies collect information in a way that does not directly identify anyone. For more information on how these cookies work, please see our Cookies Policy.